V
NVAX icon

Veritable’s Novavax NVAX Stock Holding History

Veritable’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,477
Closed -$211K – 937
2021
Q4 		$211K Sell
1,477
-202
-12% -$34.7K ﹤0.01% 867
2021
Q3 		$348K Buy
1,679
+190
+13% +$41.9K 0.01% 641
2021
Q2 		$316K Buy
1,489
+38
+3% +$6.96K 0.01% 669
2021
Q1 		$263K Buy
+1,451
New +$289K ﹤0.01% 695
2016
Q3 		– Sell
-700
Closed -$102K – 739
2016
Q2 		$102K Buy
+700
New +$80.2K ﹤0.01% 702

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Veritable's NVAX Position: Q1 2022 in Review

Veritable sold out of Novavax (NVAX) in Q1 2022, closing a stake of 1,477 shares — an estimated $211K sold.

Veritable first reported a position in NVAX in Q2 2016 and held it in 5 quarters. The position peaked at $348K in Q3 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

  • Veritable reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
  • Veritable sold 1,477 Novavax shares in Q1 2022, an estimated $211K.
  • Veritable first reported a position in Novavax in Q2 2016 and held it in 5 quarters.
  • Veritable's Novavax position peaked at $348K in Q3 2021.
  • 381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on Veritable's 13F filing for Q1 2022, filed 11 May 2022.